In chronic myeloid leukemia (CML), the progress from chronic phase (CP) to advanced disease with accelerated phase (AP) or blast phase (BP) is frequently accompanied or preceded by cytogenetic evolution within the Philadelphia-positive (Ph þ ) clones: although in CP additional chromosomal alterations are identified in o5% of patients only, their frequency increases to 30% in AP and up to 80% in patients with BP. 1 This phenomenon is believed to reflect the genetic instability of CML. 1 It was clearly shown that the additional chromosomal alterations follow nonrandom patterns: 2 The 'major route changes' comprise alterations such as trisomy 8, isochromosome i(17q) or an extra Philadelphia chromosome. Diverse numerical abnormalities (for example, monosomy 7 or trisomy 21) and the t(3;21)(q26;q22) have been identified as 'minor route changes.' These specific chromosomal alterations are associated with diverse prognostic profiles: although alterations such as the t(3;21) are indicative of an adverse prognosis and rapid progression to BP, othersFfor example, trisomy 8Fare less unfavorable. Corresponding to the pre-imatinib era, the Ph þ clonal cytogenetic evolution was still identified to worsen prognosis in patients receiving imatinib, 3 although good responses to imatinib were still possible. 4 In a cohort of 141 patients having received treatment with imatinib for CP following interferon failure, O'Dwyer et al. 5 described a 50% relapse risk in patients with clonal evolution in contrast to 3% in those without evidence of this phenomenon.
Thus, the clinical impact of Ph þ clonal evolution in patients receiving imatinib has been investigated in several studies. However, whether the introduction of tyrosine kinase inhibitors (TKIs) has induced changes in these cytogenetic patterns, remains to be clarified, as all respective studies were performed before the introduction of imatinib. 2 We here compared two subgroups: (1) The 245 patients from our cohort were retrospectively selected for this study because of the detection of additional cytogenetic abnormalities in the Ph þ clones at diagnosis of CML or during the course of disease. There were 172 males and 73 females (median age, 60.7 years; range, 17.9-90.3) with different stages of CML. Bone marrow (or, in occasional cases, peripheral blood) samples were sent for diagnostic workup to the MLL between August 2005 and June 2009. Patients received treatment with imatinib or with the second-generation TKIs dasatinib and nilotinib. In 91 patients, additional cytogenetic abnormalities in the Ph þ clone were identified at diagnosis of the CML, whereas 154 patients acquired them during the course of disease during treatment with TKIs. The phase of CML was known in 134 patients: 93 patients had CP, 13 had AP and 28 suffered from BP. Patients analyzed at MLL gave written informed consent to laboratory and genetic analyses and the use of data for research studies. The diagnostic workup of the samples included cytomorphology, cytogenetics combined with interphase fluorescence in situ hybridization and molecular genetics.
Cytogenetic results were interpreted according to the International System for Human Cytogenetic Nomenclature (ISCN). Major route abnormalities were defined as follows: þ 8, þ der(22)t(9;22) ( þ Phil), þ 19, and i(17)(q10); minor route abnormalities were þ 17, þ 21, ÀY, À7, À17 and the t(3;21)(q26;q22). Chromosomal gains and losses were analyzed with the support of the CyDAS, that is, a cytogenetic data analysis system. Within this novel system, which recently has been developed by Rieder and co-workers, 6 the numbers of cases showing the respective cytogenetic gains or losses were visualized by the thickness of the bars corresponding to the respective chromosomal regions (http://www.cydas.org/ OnlineAnalysis/). First, analysis was carried out for the Mitelman cohort ( Figure 1a ) and for the whole cohort from the MLL (n ¼ 245) (Figure 1b) . Later, a separate analysis was carried out for those patients from the MLL cohort who showed Ph þ clonal evolution already at diagnosis of CML, for example, before the start of TKIs (n ¼ 91; Figure 1c ) and for those patients who developed Ph þ cytogenetic alterations under TKI treatment (n ¼ 154; Figure 1d) .
As a result, all four cohorts showed comparable patterns of chromosomal gains and losses in addition to the t(9;22): most frequent were þ 8, þ Ph chromosome, þ 19 and i(17)(q10), representing classical 'major route abnormalities,' and ÀY (a minor route abnormality). Less frequent were À7 and þ 21 (from the minor route as well). As there was no difference between the characterization of the additional cytogenetic abnormalities in the Mitelman cohort (dating from the preimatinib era) (Figure 1a ) and the Munich cohort, in which all patients had undergone TKI treatment (Figure 1b) , the introduction of TKI did not seem to alter these cytogenetic patterns. It further should be mentioned that there was no difference between the cytogenetic patterns in patients who showed Philadelphia clonal evolution at diagnosis (Figure 1c ) or during treatment with TKIs (Figure 1d) .
Finally, we analyzed the complexity of the karyotypes depending on the stage of CML in the cohort from our laboratory. Patients with advanced disease (AP/BP, n ¼ 41) had higher numbers of additional cytogenetic alterations (median: n ¼ 2; range 1-36) compared with those 93 patients with CP (n ¼ 1; range 1-10) (Po0.01). In more detail, patients with advanced disease had higher numbers of unbalanced additional alterations (median: n ¼ 2; range 0-36) than those with CP (median: n ¼ 1; range, 0-10), whereas the numbers of balanced translocations did not significantly differ between patients with advanced disease (median: n ¼ 0; range, 0-2) and CP (median: n ¼ 0; range, 0-3).
In conclusion, this study shows similar patterns of cytogenetic alterations in the Ph þ clones as investigated in the pre-imatinib and the imatinib era. This was independent of the time point of analysis at diagnosis or during follow-up under TKI treatment. This suggests that the pathways of Ph þ clonal evolution are independent from the effects of TKIs. Apparently, TKIs do not seem to select specific Philadelphia cytogenetic alterations. This differs from previous observations in recipients of allogeneic stem cell transplantation (SCT), as differences in the cytogenetic evolution patterns had been observed compared with patients who received conventional treatment. In the study of Karrman et al., 7 there was a lower frequency of major route abnormalities in recipients of allogeneic SCT (15%) when compared with those patients having received an autologous SCT (two from three patients with Ph þ clones). Chase et al. 8 reported a high frequency of translocations and deletions involving 13q in recipients of allo-SCT who showed relapse or persistent disease. Therefore, allo-SCT seems to alter the biology in the Ph þ clones in patients with relapsing or persistent CML, whereas TKIs have no such effect and do not interfere with the pathways of Ph þ clonal evolution. Finally, this study also analyzes the potential of novel visualizing tools to pick up patterns of cytogenetic alterations in hundreds of patients paving the way to new insights into the genetic pathways in leukemias. An inverse relationship was reported between maximum serum ferritin concentration during follow-up and median overall survival. 1 Nevertheless, whether iron overload is a surrogate marker of the severity of the disease or affects the outcome independently by end-organ damage is still controversial. 2 Tefferi and Stone 3 expressed, in a recent Editorial in this Journal, their concerns about the true weight of iron overload in the survival of MDS patients.
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The clinical and biological heterogeneity of MDS makes it difficult to control for differences while designing or analyzing research, particularly in retrospective studies. The aim of this study was to determine whether high levels of serum ferritin are independently associated with a shorter survival in MDS patients, by carefully adjusting for possible susceptibility biases through statistical adjustment and stratification models.
Between January 1992 and March 2009, 268 patients were diagnosed with MDS. We excluded patients who underwent intensive chemotherapy (n ¼ 35), or responded to erythropoietin treatment (n ¼ 23) or iron chelation (n ¼ 11) (whose survival, transfusion requirements and serum ferritin levels could be altered). We also excluded those patients without, at least, a serum ferritin determination during the follow-up (n ¼ 23). One hundred and seventy-six patients fulfilled the inclusion criteria and remained for analysis. In each patient the following variables were examined as possible prognostic factors: age, gender, International Prognostic Scoring System (IPSS) score, platelet mass, lactate dehydrogenase (LDH) levels, development of transfusion requirement and maximum ferritin level reached through follow-up. We considered ferritin levels during the outpatient follow-up, not taking into account determinations performed during hospital admissions, to avoid a measurement bias of ferritin as an acute-phase reactant. Statistical analysis was performed using SPSS 15.0 (SPSS, Chicago, IL, USA) except for statistical power, which was calculated by using GraphPad Statmate 2.0 (GraphPad, San Diego, CA, USA).
The median patient age was 74 years (interquartile range (IQR) 65-79 years), with a male predominance (56%, n ¼ 98). The median follow-up was 22 months (range 1-71 months). Of these patients, 28 (16%) transformed to acute myelogenous
